Immunotherapy of cancer—Introduction
✍ Scribed by Yosef H. Pilch
- Publisher
- Springer
- Year
- 1977
- Tongue
- English
- Weight
- 218 KB
- Volume
- 1
- Category
- Article
- ISSN
- 0364-2313
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e., Ta, Tl, and carcinoma in situ) with specific objectives which include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression,
122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 ؋ 10 6 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy